{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T15:07:14Z","timestamp":1782918434664,"version":"3.54.5"},"reference-count":274,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,8,30]],"date-time":"2022-08-30T00:00:00Z","timestamp":1661817600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"<jats:p>The integration of pharmacotherapy with psychosocial interventions has an important role to play in the improvement of functional outcome of subjects with schizophrenia (SCZ), in all stages of the disorder. It is essential for the adequate management of unmet therapeutic needs, such as negative symptoms and cognitive dysfunctions which account for most of the functional impairment of subjects with SCZ and do not respond to available antipsychotics. Enhancing the knowledge on factors involved in the effectiveness of integrated treatment plans is an important step forward for SCZ care. This review aims to identify factors that might influence the impact of integrated treatments on functional outcome. Most studies on the impact of psychosocial treatments on functional outcome of subjects with SCZ did not control for the effect of prescribed antipsychotics or concomitant medications. However, several factors relevant to ongoing pharmacological treatment might influence the outcome of integrated therapy, with an impact on the adherence to treatment (e.g., therapeutic alliance and polypharmacotherapy) or on illness-related factors addressed by the psychosocial interventions (e.g., cognitive dysfunctions or motivational deficits). Indirect evidence suggests that treatment integration should consider the possible detrimental effects of different antipsychotics or concomitant medications on cognitive functions, as well as on secondary negative symptoms. Cognitive dysfunctions can interfere with participation to an integrated treatment plan and can be worsened by extrapyramidal or metabolic side effects of antipsychotics, or concomitant treatment with anticholinergics or benzodiazepines. Secondary negative symptoms, due to positive symptoms, sedation, extrapyramidal side effects or untreated depression, might cause early drop-out and poor adherence to treatment. Researchers and clinicians should examine all the above-mentioned factors and implement appropriate and personalized integrated treatments to improve the outcome of SCZ.<\/jats:p>","DOI":"10.3389\/fpsyt.2022.970210","type":"journal-article","created":{"date-parts":[[2022,8,30]],"date-time":"2022-08-30T04:48:09Z","timestamp":1661834889000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":26,"title":["Factors influencing the outcome of integrated therapy approach in schizophrenia: A narrative review of the literature"],"prefix":"10.3389","volume":"13","author":[{"given":"Giulia M.","family":"Giordano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Brando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pasquale","family":"Pezzella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"De Angelis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armida","family":"Mucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvana","family":"Galderisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,8,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/S0140-6736(15)01121-6","article-title":"Schizophrenia","volume":"388","author":"Owen","year":"2016","journal-title":"Lancet."},{"key":"B2","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1176\/appi.ajp.2016.16050503","article-title":"Treatment-resistant schizophrenia: treatment response and resistance in psychosis (TRRIP) working group consensus guidelines on diagnosis and terminology","volume":"174","author":"Howes","year":"2017","journal-title":"Am J Psychiatry."},{"key":"B3","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1007\/s11920-019-1091-3","article-title":"Non-genetic factors in schizophrenia","volume":"21","author":"Stilo","year":"2019","journal-title":"Curr Psychiatry Rep."},{"key":"B4","doi-asserted-by":"publisher","first-page":"519","DOI":"10.2147\/NDT.S225643","article-title":"Negative symptoms in schizophrenia: a review and clinical guide for recognition, assessment, and treatment","volume":"16","author":"Correll","year":"2020","journal-title":"Neuropsychiatr Dis Treat."},{"key":"B5","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1002\/wps.20700","article-title":"The interplay among psychopathology, personal resources, context-related factors and real-life functioning in schizophrenia: stability in relationships after 4 years and differences in network structure between recovered and non-recovered patients","volume":"19","author":"Galderisi","year":"2020","journal-title":"World Psychiatry."},{"key":"B6","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1002\/wps.20809","article-title":"The clinical characterization of the patient with primary psychosis aimed at personalization of management","volume":"20","author":"Maj","year":"2021","journal-title":"World Psychiatry."},{"key":"B7","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.schres.2021.07.010","article-title":"Interindividual variability of functional connectome in schizophrenia","volume":"235","author":"Santo-Angles","year":"2021","journal-title":"Schizophr Res."},{"key":"B8","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1111\/pcn.12322","article-title":"Schizophrenia in 2020: trends in diagnosis and therapy","volume":"69","author":"Gaebel","year":"2015","journal-title":"Psychiatry Clin Neurosci."},{"key":"B9","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/978-3-319-70554-5_35","article-title":"Trends in schizophrenia diagnosis and treatment","volume-title":"Advances in Psychiatry.","author":"Gaebel","year":"2019"},{"key":"B10","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1002\/wps.20693","article-title":"Dopamine and glutamate in schizophrenia: biology, symptoms and treatment","volume":"19","author":"McCutcheon","year":"2020","journal-title":"World Psychiatry."},{"key":"B11","doi-asserted-by":"publisher","first-page":"653642","DOI":"10.3389\/fpsyt.2021.653642","article-title":"EEG-based measures in at-risk mental state and early stages of schizophrenia: a systematic review","volume":"12","author":"Perrottelli","year":"2021","journal-title":"Front Psychiatry"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1016\/S0140-6736(17)32154-2","article-title":"Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016","volume":"390","year":"2017","journal-title":"Lancet"},{"key":"B13","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(08)61764-X","article-title":"Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis","volume":"373","author":"Leucht","year":"2009","journal-title":"Lancet"},{"key":"B14","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.wpsyc.2012.05.004","article-title":"Predicting the severity of everyday functional disability in people with schizophrenia: cognitive deficits, functional capacity, symptoms, and health status","volume":"11","author":"Harvey","year":"2012","journal-title":"World Psychiatry."},{"key":"B15","doi-asserted-by":"publisher","first-page":"S165","DOI":"10.1093\/schbul\/sbu006","article-title":"Schizophrenia\u2013time to commit to policy change","volume":"40","author":"Fleischhacker","year":"2014","journal-title":"Schizophr Bull."},{"key":"B16","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1002\/wps.20167","article-title":"The influence of illness-related variables, personal resources and context-related factors on real-life functioning of people with schizophrenia","volume":"13","author":"Galderisi","year":"2014","journal-title":"World Psychiatry."},{"key":"B17","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1093\/schbul\/sbx082","article-title":"Social disconnection in schizophrenia and the general community","volume":"44","author":"Green","year":"2018","journal-title":"Schizophr Bull."},{"key":"B18","doi-asserted-by":"publisher","first-page":"2043808719865693","DOI":"10.1177\/2043808719865693","article-title":"Prediction of disability in schizophrenia: symptoms, cognition, and self-assessment","volume":"10","author":"Harvey","year":"2019","journal-title":"J Exp Psychopathol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1001\/archpsyc.64.10.1123","article-title":"A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time?","volume":"64","author":"Saha","year":"2007","journal-title":"Arch Gen Psychiatry."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1093\/schbul\/sbs130","article-title":"A systematic review and meta-analysis of recovery in schizophrenia","volume":"39","author":"J\u00e4\u00e4skel\u00e4inen","year":"2013","journal-title":"Schizophr Bull"},{"key":"B21","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1002\/wps.20194","article-title":"Recovery, not progressive deterioration, should be the expectation in schizophrenia","volume":"14","author":"Zipursky","year":"2015","journal-title":"World Psychiatry."},{"key":"B22","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1097\/YCO.0000000000000407","article-title":"Recovery from schizophrenia: is it possible?","volume":"31","author":"Vita","year":"2018","journal-title":"Curr Opin Psychiatry."},{"key":"B23","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1017\/S1355617708080600","article-title":"Functional implications of neuropsychological normality and symptom remission in older outpatients diagnosed with schizophrenia: a cross-sectional study","volume":"14","author":"Leung","year":"2008","journal-title":"J Int Neuropsychol Soc."},{"key":"B24","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.schres.2013.04.022","article-title":"Assessment of everyday functioning in schizophrenia: implications for treatments aimed at negative symptoms","volume":"150","author":"Harvey","year":"2013","journal-title":"Schizophr Res."},{"key":"B25","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.schres.2016.04.043","article-title":"Pathways to functional outcome in subjects with schizophrenia living in the community and their unaffected first-degree relatives","volume":"175","author":"Galderisi","year":"2016","journal-title":"Schizophr Res."},{"key":"B26","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1001\/jamapsychiatry.2017.4607","article-title":"Interplay among psychopathologic variables, personal resources, context-related factors, and real-life functioning in individuals with schizophrenia: a network analysis","volume":"75","author":"Galderisi","year":"2018","journal-title":"JAMA Psychiatry."},{"key":"B27","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1192\/j.eurpsy.2021.135","article-title":"Factors associated with real-life functioning in persons with schizophrenia in a 4-year follow-up study of the Italian network for research on psychoses","volume":"78","author":"Mucci","year":"2021","journal-title":"JAMA Psychiatry."},{"key":"B28","doi-asserted-by":"publisher","first-page":"791117","DOI":"10.3389\/fpsyt.2021.791117","article-title":"Improving knowledge on pathways to functional outcome in schizophrenia: main results from the italian network for research on psychoses","volume":"12","author":"Giuliani","year":"2021","journal-title":"Front Psychiatry."},{"key":"B29","doi-asserted-by":"publisher","first-page":"e21","DOI":"10.1192\/j.eurpsy.2021.13","article-title":"EPA guidance on treatment of negative symptoms in schizophrenia","volume":"64","author":"Galderisi","year":"2021","journal-title":"Eur Psychiatry."},{"key":"B30","first-page":"12","article-title":"When does cognitive decline occur in the period prior to the first episode of schizophrenia?","volume":"6","author":"Harvey","year":"2009","journal-title":"Psychiatry."},{"key":"B31","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.euroneuro.2012.04.019","article-title":"Persistent negative symptoms in first episode patients with schizophrenia: results from the European First Episode Schizophrenia Trial","volume":"23","author":"Galderisi","year":"2013","journal-title":"Eur Neuropsychopharmacol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.schres.2015.07.021","article-title":"Long-term trajectories of positive and negative symptoms in first episode psychosis: a 10year follow-up study in the OPUS cohort","volume":"168","author":"Austin","year":"2015","journal-title":"Schizophr Res."},{"key":"B33","doi-asserted-by":"publisher","first-page":"7","DOI":"10.9758\/cpn.2018.16.1.7","article-title":"Cognitive deficits in schizophrenia: understanding the biological correlates and remediation strategies","volume":"16","author":"Tripathi","year":"2018","journal-title":"Clin Psychopharmacol Neurosci."},{"key":"B34","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.chc.2019.08.008","article-title":"Cognition, social cognition, and functional capacity in early-onset schizophrenia","volume":"29","author":"Harvey","year":"2020","journal-title":"Child Adolesc Psychiatr Clin N Am."},{"key":"B35","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.schres.2012.08.023","article-title":"Cognitive and clinical predictors of functional capacity in patients with first episode schizophrenia","volume":"141","author":"Vesterager","year":"2012","journal-title":"Schizophr Res."},{"key":"B36","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1002\/wps.20729","article-title":"What is resilience: an affiliative neuroscience approach","volume":"19","author":"Feldman","year":"2020","journal-title":"World Psychiatry."},{"key":"B37","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1093\/schbul\/sbac018","article-title":"The puzzle of functional recovery in schizophrenia-spectrum disorders-replicating a network analysis study","volume":"48","author":"Moura","year":"2022","journal-title":"Schizophr Bull."},{"key":"B38","first-page":"168","article-title":"Integrated treatment of schizophrenia","volume":"21","author":"Altamura","year":"2015"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1176\/appi.ps.54.11.1499","article-title":"Integrated treatment of schizophrenia","volume":"54","author":"Lenroot","year":"2003","journal-title":"Psychiatr Serv"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.2147\/NDT.S49263","article-title":"Current approaches to treatments for schizophrenia spectrum disorders, part II: psychosocial interventions and patient-focused perspectives in psychiatric care","volume":"9","author":"Chien","year":"2013","journal-title":"Neuropsychiatr Dis Treat"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.2147\/NDT.S37485","article-title":"Current approaches to treatments for schizophrenia spectrum disorders, part I: an overview and medical treatments","volume":"9","author":"Chien","year":"2013","journal-title":"Neuropsychiatr Dis Treat"},{"key":"B42","doi-asserted-by":"publisher","first-page":"74","DOI":"10.5498\/wjp.v2.i5.74","article-title":"Medication adherence in schizophrenia","volume":"2","author":"Acosta","year":"2012","journal-title":"World J Psychiatry"},{"key":"B43","doi-asserted-by":"publisher","first-page":"892","DOI":"10.4088\/JCP.v63n1007","article-title":"Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature","volume":"63","author":"Lacro","year":"2002","journal-title":"J Clin Psychiatry"},{"key":"B44","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1177\/0269881110391123","article-title":"Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology","volume":"25","author":"Barnes","year":"2011","journal-title":"J Psychopharmacol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"100","DOI":"10.3389\/fpsyt.2017.00100","article-title":"Rehabilitation interventions to promote recovery from schizophrenia: a systematic review","volume":"8","author":"Morin","year":"2017","journal-title":"Front Psychiatry"},{"key":"B46","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1097\/00131746-200611000-00003","article-title":"Strategies for maximizing clinical effectiveness in the treatment of schizophrenia","volume":"12","author":"Tandon","year":"2006","journal-title":"J Psychiatr Pract."},{"key":"B47","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1093\/schbul\/sbn177","article-title":"Psychosocial treatments to promote functional recovery in schizophrenia","volume":"35","author":"Kern","year":"2009","journal-title":"Schizophr Bull"},{"key":"B48","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.3389\/fphar.2018.01542","article-title":"Factors associated with response and resistance to cognitive remediation in schizophrenia: a critical review","volume":"9","author":"Barlati","year":"2018","journal-title":"Front Pharmacol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"Cd000088","DOI":"10.1002\/14651858.CD000088.pub3","article-title":"Family intervention for schizophrenia","volume":"12","author":"Pharoah","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"B50","volume-title":"National Institute for Health and Clinical Excellence: Guidance. Schizophrenia: Core Interventions in the Treatment and Management of Schizophrenia in Primary and Secondary Care (Update)","year":"2009"},{"key":"B51","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1093\/schbul\/sbm114","article-title":"Cognitive behavior therapy for schizophrenia: effect sizes, clinical models, and methodological rigor","volume":"34","author":"Wykes","year":"2008","journal-title":"Schizophr Bull."},{"key":"B52","doi-asserted-by":"publisher","first-page":"145","DOI":"10.3109\/08039488.2013.789074","article-title":"Cognitive model and cognitive behavior therapy for schizophrenia: an overview","volume":"68","author":"Sarin","year":"2014","journal-title":"Nord J Psychiatry."},{"key":"B53","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1186\/s12888-016-0912-8","article-title":"Disability and recovery in schizophrenia: a systematic review of cognitive behavioral therapy interventions","volume":"16","author":"Nowak","year":"2016","journal-title":"BMC Psychiatry."},{"key":"B54","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s40359-018-0243-2","article-title":"Cognitive behavioural therapy for schizophrenia - outcomes for functioning, distress and quality of life: a meta-analysis","volume":"6","author":"Laws","year":"2018","journal-title":"BMC Psychology"},{"key":"B55","first-page":"57","article-title":"Cognitive remediation \u2013 where are we now and what should we do next?","volume":"24","author":"Wykes","year":"2018","journal-title":"The Journal of Psychopathol"},{"key":"B56","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1017\/S0033291720000872","article-title":"Cognitive remediation for inpatients with psychosis: a systematic review and meta-analysis","volume":"50","author":"Cella","year":"2020","journal-title":"Psychol Med"},{"key":"B57","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1016\/j.neubiorev.2019.09.031","article-title":"Multi-outcome meta-analysis (MOMA) of cognitive remediation in schizophrenia: revisiting the relevance of human coaching and elucidating interplay between multiple outcomes","volume":"107","author":"Kambeitz-Ilankovic","year":"2019","journal-title":"Neurosci Biobehav Rev"},{"key":"B58","first-page":"1","article-title":"Acceptability of cognitive remediation for schizophrenia: a systematic review and meta-analysis of randomized controlled trials","volume-title":"Psychol Med","author":"Vita","year":"2022"},{"key":"B59","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1001\/jamapsychiatry.2021.0620","article-title":"Effectiveness, core elements, and moderators of response of cognitive remediation for schizophrenia a systematic review and meta-analysis of randomized clinical trials","volume":"78","author":"Vita","year":"2021","journal-title":"JAMA Psychiatry"},{"key":"B60","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1176\/appi.ajp.2010.10060855","article-title":"A meta-analysis of cognitive remediation for schizophrenia: methodology and effect sizes","volume":"168","author":"Wykes","year":"2011","journal-title":"Am J Psychiatry"},{"key":"B61","doi-asserted-by":"publisher","first-page":"156084","DOI":"10.1155\/2013\/156084","article-title":"Cognitive remediation in schizophrenia: current status and future perspectives","volume":"2013","author":"Barlati","year":"2013","journal-title":"Schizophr Res Treatment."},{"key":"B62","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.cpr.2016.11.009","article-title":"Cognitive remediation for negative symptoms of schizophrenia: a network meta-analysis","volume":"52","author":"Cella","year":"2017","journal-title":"Clin Psychol Rev"},{"key":"B63","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1017\/S0033291717000757","article-title":"Effects of cognitive remediation on negative symptoms dimensions: exploring the role of working memory","volume":"47","author":"Cella","year":"2017","journal-title":"Psychol Med"},{"key":"B64","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1192\/bjp.bp.116.197103","article-title":"Psychological and psychosocial interventions for negative symptoms in psychosis: systematic review and meta-analysis","volume":"210","author":"Lutgens","year":"2017","journal-title":"Br J Psychiatry"},{"key":"B65","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1002\/wps.20760","article-title":"Effectiveness of cognitive remediation in the ultra-high risk state for psychosis","volume":"19","author":"Glenth\u00f8j","year":"2020","journal-title":"World Psychiatry."},{"key":"B66","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1093\/schbul\/sbx146","article-title":"A Meta-analysis of social skills training and related interventions for psychosis","volume":"44","author":"Turner","year":"2018","journal-title":"Schizophr Bull"},{"key":"B67","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/B978-0-12-817752-5.00017-2","article-title":"Chapter 17 - social skills training for persons with schizophrenia","volume-title":"Social Skills Across the Life Span","author":"Browne","year":"2020"},{"key":"B68","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.schres.2004.12.020","article-title":"Integrated treatment ameliorates negative symptoms in first episode psychosis\u2013results from the Danish OPUS trial","volume":"79","author":"Thorup","year":"2005","journal-title":"Schizophr Res."},{"key":"B69","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1111\/bjc.12320","article-title":"A meta-analysis of the effects of social-cognitive training in schizophrenia: the role of treatment characteristics and study quality","volume":"61","author":"Yeo","year":"2022","journal-title":"Br J Clin Psychol."},{"key":"B70","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1001\/jamapsychiatry.2018.0623","article-title":"Comparison of early intervention services vs treatment as usual for early-phase psychosis: a systematic review, meta-analysis, and meta-regression","volume":"75","author":"Correll","year":"2018","journal-title":"JAMA Psychiatry"},{"key":"B71","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1002\/wps.20708","article-title":"Early intervention in psychosis in low- and middle-income countries: a WPA initiative","volume":"19","author":"Singh","year":"2020","journal-title":"World Psychiatry."},{"key":"B72","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/S2215-0366(18)30096-8","article-title":"Antipsychotic drugs versus cognitive behavioural therapy versus a combination of both in people with psychosis: a randomised controlled pilot and feasibility study","volume":"5","author":"Morrison","year":"2018","journal-title":"Lancet Psychiatry."},{"key":"B73","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1177\/2045125312474019","article-title":"Medication adherence in schizophrenia: factors influencing adherence and consequences of nonadherence, a systematic literature review","volume":"3","author":"Higashi","year":"2013","journal-title":"Therap Adv Psychopharmacol"},{"key":"B74","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.schres.2014.11.018","article-title":"Extrapyramidal symptoms and cognitive test performance in patients with schizophrenia","volume":"161","author":"Fervaha","year":"2015","journal-title":"Schizophr Res."},{"key":"B75","doi-asserted-by":"publisher","first-page":"110250","DOI":"10.1016\/j.pnpbp.2021.110250","article-title":"Prevalence of antipsychotic-induced extrapyramidal symptoms and their association with neurocognition and social cognition in outpatients with schizophrenia in the \u201creal-life\u201d","volume":"109","author":"Monteleone","year":"2021","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry."},{"key":"B76","doi-asserted-by":"publisher","first-page":"622","DOI":"10.3389\/fpsyt.2018.00622","article-title":"Antipsychotics, metabolic adverse effects, and cognitive function in schizophrenia","volume":"9","author":"MacKenzie","year":"2018","journal-title":"Front Psychiatry"},{"key":"B77","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s00406-017-0787-9","article-title":"Benzodiazepine long-term administration is associated with impaired attention\/working memory in schizophrenia: results from the national multicentre FACE-SZ data set","volume":"268","author":"Fond","year":"2018","journal-title":"Eur Arch Psychiatry Clin Neurosci."},{"key":"B78","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1176\/appi.ajp.2020.20081212","article-title":"Anticholinergic Medication Burden-Associated Cognitive Impairment in Schizophrenia","volume":"178","author":"Joshi","year":"2021","journal-title":"Am J Psychiatry."},{"key":"B79","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1093\/schbul\/sbaa093","article-title":"The impact of anticholinergic burden on functional capacity in persons with schizophrenia across the adult life span","volume":"47","author":"Khan","year":"2021","journal-title":"Schizophr Bull."},{"key":"B80","first-page":"10","article-title":"Factors influencing compliance in schizophrenia patients","volume":"64","author":"Fleischhacker","year":"2003","journal-title":"J Clin Psychiatry"},{"key":"B81","doi-asserted-by":"crossref","DOI":"10.1017\/9781108163682","volume-title":"Cognitive Enhancement in Schizophrenia and Related Disorders","author":"Keshavan","year":"2019"},{"key":"B82","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1016\/S0140-6736(12)60239-6","article-title":"Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis","volume":"379","author":"Leucht","year":"2012","journal-title":"Lancet"},{"key":"B83","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.schres.2017.10.018","article-title":"Dimensional symptom severity and global cognitive function predict subjective quality of life in patients with schizophrenia and healthy adults","volume":"195","author":"DeRosse","year":"2018","journal-title":"Schizophr Res."},{"key":"B84","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1093\/schbul\/sbs097","article-title":"Guideline-concordant antipsychotic use and mortality in schizophrenia","volume":"39","author":"Cullen","year":"2012","journal-title":"Schizophr Bull."},{"key":"B85","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1002\/wps.20384","article-title":"Excess mortality in persons with severe mental disorders: a multilevel intervention framework and priorities for clinical practice, policy and research agendas","volume":"16","author":"Liu","year":"2017","journal-title":"World Psychiatry."},{"key":"B86","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/sj.mp.4001556","article-title":"Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs","volume":"10","author":"Miyamoto","year":"2005","journal-title":"Mol Psychiatry."},{"key":"B87","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1177\/0706743717719897","article-title":"Canadian schizophrenia guidelines: introduction and guideline development process","volume":"62","author":"Pringsheim","year":"2017","journal-title":"Can J Psychiatry."},{"key":"B88","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1177\/0706743718760288","article-title":"The assessment and treatment of antipsychotic-induced Akathisia","volume":"63","author":"Pringsheim","year":"2018","journal-title":"Can J Psychiatry"},{"key":"B89","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1007\/s00406-020-01207-x","article-title":"Characteristics associated with self-reported medication adherence in persons with psychosis referred to psychosocial rehabilitation centers","volume":"271","author":"Verdoux","year":"2021","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"B90","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1002\/wps.20699","article-title":"20-year follow-up study of physical morbidity and mortality in relationship to antipsychotic treatment in a nationwide cohort of 62,250 patients with schizophrenia (FIN20)","volume":"19","author":"Taipale","year":"2020","journal-title":"World psychiatry."},{"key":"B91","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1038\/nrendo.2017.183","article-title":"Side effects of olanzapine worsened by metabolic dysfunction","volume":"14","author":"Leong","year":"2018","journal-title":"Nat Rev Endocrinol"},{"key":"B92","doi-asserted-by":"publisher","first-page":"e7","DOI":"10.1192\/j.eurpsy.2020.115","article-title":"Identification and management of cardiometabolic risk in subjects with schizophrenia spectrum disorders: a Delphi expert consensus study","volume":"64","author":"Galderisi","year":"2021","journal-title":"Eur Psychiatry."},{"key":"B93","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1038\/s41467-017-00716-z","article-title":"Extrapyramidal side effects of antipsychotics are linked to their association kinetics at dopamine D(2) receptors","volume":"8","author":"Sykes","year":"2017","journal-title":"Nat Commun."},{"key":"B94","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.psc.2016.01.008","article-title":"Detecting and managing adverse effects of antipsychotic medications: current state of play","volume":"39","author":"Ames","year":"2016","journal-title":"Psychiatr Clin North Am"},{"key":"B95","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1159\/000437430","article-title":"Olanzapine is faster than haloperidol in inducing metabolic abnormalities in schizophrenic and bipolar patients","volume":"72","author":"Fabrazzo","year":"2015","journal-title":"Neuropsychobiology."},{"key":"B96","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1177\/0269881120944156","article-title":"Neurobiological mechanisms associated with antipsychotic drug-induced dystonia","volume":"35","author":"Loonen","year":"2021","journal-title":"J Psychopharmacol."},{"key":"B97","doi-asserted-by":"publisher","first-page":"246","DOI":"10.4088\/JCP.18m12246","article-title":"Prevalence of and risk factors for extrapyramidal side effects of antipsychotics: results from the national FACE-SZ cohort","volume":"80","author":"Misdrahi","year":"2019","journal-title":"J Clin Psychiatry"},{"key":"B98","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1038\/sj.clpt.6100069","article-title":"Risk of extrapyramidal syndrome in schizophrenic patients treated with antipsychotics: a population-based study","volume":"81","author":"Yang","year":"2007","journal-title":"Clin Pharmacol Ther."},{"key":"B99","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1093\/schbul\/sbq042","article-title":"Second-generation antipsychotic drugs and extrapyramidal side effects: a systematic review and meta-analysis of head-to-head comparisons","volume":"38","author":"Rummel-Kluge","year":"2012","journal-title":"Schizophr Bull"},{"key":"B100","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","article-title":"Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis","volume":"382","author":"Leucht","year":"2013","journal-title":"Lancet"},{"key":"B101","doi-asserted-by":"publisher","first-page":"757","DOI":"10.2147\/TCRM.S117321","article-title":"Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review","volume":"13","author":"Solmi","year":"2017","journal-title":"Ther Clin Risk Manag"},{"key":"B102","doi-asserted-by":"publisher","first-page":"e23","DOI":"10.1192\/j.eurpsy.2021.11","article-title":"EPA guidance on assessment of negative symptoms in schizophrenia","volume":"64","author":"Galderisi","year":"2021","journal-title":"Eur Psychiatry."},{"key":"B103","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1016\/S2215-0366(18)30050-6","article-title":"Negative symptoms of schizophrenia: new developments and unanswered research questions","volume":"5","author":"Galderisi","year":"2018","journal-title":"Lancet Psychiatry"},{"key":"B104","doi-asserted-by":"publisher","first-page":"438","DOI":"10.2337\/diacare.20.3.438","article-title":"Is type II diabetes associated with an increased risk of cognitive dysfunction? A critical review of published studies","volume":"20","author":"Strachan","year":"1997","journal-title":"Diabetes Care."},{"key":"B105","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1111\/1467-9280.00288","article-title":"Amnesia is a deficit in relational memory","volume":"11","author":"Ryan","year":"2000","journal-title":"Psychol Sci."},{"key":"B106","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/j.neuropsychologia.2003.08.011","article-title":"Processing and short-term retention of relational information in amnesia","volume":"42","author":"Ryan","year":"2004","journal-title":"Neuropsychologia."},{"key":"B107","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1159\/000081049","article-title":"Cardiovascular risk factors and cognitive function in adults 30-59 years of age (NHANES III)","volume":"24","author":"Pavlik","year":"2005","journal-title":"Neuroepidemiology."},{"key":"B108","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1210\/jc.2006-2540","article-title":"Hypothalamic-pituitary-adrenal axis dysregulation and memory impairments in type 2 diabetes","volume":"92","author":"Bruehl","year":"2007","journal-title":"J Clin Endocrinol Metab."},{"key":"B109","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.schres.2012.09.019","article-title":"Relationship between metabolic syndrome and cognition in patients with schizophrenia","volume":"142","author":"Lindenmayer","year":"2012","journal-title":"Schizophr Res."},{"key":"B110","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1097\/NMD.0000000000000124","article-title":"Metabolic syndrome and its factors affect cognitive function in chronic schizophrenia complicated by metabolic syndrome","volume":"202","author":"Li","year":"2014","journal-title":"J Nerv Ment Dis."},{"key":"B111","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1017\/S0033291716003366","article-title":"The relationship between cognitive impairment in schizophrenia and metabolic syndrome: a systematic review and meta-analysis","volume":"47","author":"Bora","year":"2017","journal-title":"Psychol Med"},{"key":"B112","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1111\/acps.13066","article-title":"Antipsychotic use and risk of life-threatening medical events: umbrella review of observational studies","volume":"140","author":"Papola","year":"2019","journal-title":"Acta Psychiatr Scand"},{"key":"B113","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1002\/wps.20567","article-title":"Management of common adverse effects of antipsychotic medications","volume":"17","author":"Stroup","year":"2018","journal-title":"World Psychiatry"},{"key":"B114","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1192\/apt.bp.115.014928","article-title":"Management of antipsychotic-induced hyperprolactinaemia","volume":"23","author":"Gupta","year":"2017","journal-title":"BJPsych Advances."},{"key":"B115","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.psychres.2017.06.068","article-title":"Clozapine versus other antipsychotics during the first 18 weeks of treatment: a retrospective study on risk factor increase of blood dyscrasias","volume":"256","author":"Fabrazzo","year":"2017","journal-title":"Psychiatry Res"},{"key":"B116","first-page":"1","article-title":"The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness","volume-title":"J Clin Psychiatry","author":"Velligan","year":"2009"},{"key":"B117","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.schres.2015.12.009","article-title":"The influence of medical burden severity and cognition on functional competence in older community-dwelling individuals with schizophrenia","volume":"170","author":"Tsoutsoulas","year":"2016","journal-title":"Schizophr Res."},{"key":"B118","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s00406-016-0711-8","article-title":"Neurocognitive performance, subjective well-being, and psychosocial functioning after benzodiazepine withdrawal in patients with schizophrenia or bipolar disorder: a randomized clinical trial of add-on melatonin versus placebo","volume":"267","author":"Baandrup","year":"2017","journal-title":"Eur Arch Psychiatry Clin Neurosci."},{"key":"B119","doi-asserted-by":"publisher","first-page":"112660","DOI":"10.1016\/j.psychres.2019.112660","article-title":"Benzodiazepine abuse, misuse, dependence, and withdrawal among schizophrenic patients: a review of the literature","volume":"284","author":"de la Iglesia-Larrad","year":"2020","journal-title":"Psychiatry Res"},{"key":"B120","first-page":"9","article-title":"The effects of benzodiazepines on cognition","volume":"66","author":"Stewart","year":"2005","journal-title":"J Clin Psychiatry"},{"key":"B121","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1017\/S0033291720001403","article-title":"Impact of anticholinergic load on functioning and cognitive performances of persons with psychosis referred to psychosocial rehabilitation centers","volume":"51","author":"Verdoux","year":"2020","journal-title":"Psychol Med"},{"key":"B122","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1111\/pcn.12088","article-title":"Benefits and limits of anticholinergic use in schizophrenia: focusing on its effect on cognitive function","volume":"68","author":"Ogino","year":"2014","journal-title":"Psychiatry Clin Neurosci"},{"key":"B123","doi-asserted-by":"publisher","first-page":"3199","DOI":"10.1017\/S0033291716002154","article-title":"Anticholinergic burden in schizophrenia and ability to benefit from psychosocial treatment programmes: a 3-year prospective cohort study","volume":"46","author":"O'Reilly","year":"2016","journal-title":"Psychol Med."},{"key":"B124","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.ajp.2019.10.013","article-title":"The effect of anticholinergic burden on cognitive and daily living functions in patients with schizophrenia","volume":"46","author":"Kim","year":"2019","journal-title":"Asian J Psychiatr."},{"key":"B125","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1097\/JCP.0000000000000790","article-title":"The impact of medication anticholinergic burden on cognitive performance in people with schizophrenia","volume":"37","author":"Ang","year":"2017","journal-title":"J Clin Psychopharmacol."},{"key":"B126","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.psychres.2015.11.028","article-title":"Profiling cognitive impairment in treatment-resistant schizophrenia patients","volume":"235","author":"Frydecka","year":"2016","journal-title":"Psychiatry Res."},{"key":"B127","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.schres.2017.03.034","article-title":"Cognitive burden of anticholinergic medications in psychotic disorders","volume":"190","author":"Eum","year":"2017","journal-title":"Schizophr Res."},{"key":"B128","doi-asserted-by":"publisher","first-page":"109654","DOI":"10.1016\/j.pnpbp.2019.109654","article-title":"Sexual dysfunctions are associated with major depression, chronic inflammation and anticholinergic consumption in the real-world schizophrenia FACE-SZ national cohort","volume":"94","author":"Fond","year":"2019","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry."},{"key":"B129","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1177\/2045125314553611","article-title":"Effects of discontinuing anticholinergic treatment on movement disorders, cognition and psychopathology in patients with schizophrenia","volume":"4","author":"Desmarais","year":"2014","journal-title":"Ther Adv Psychopharmacol."},{"key":"B130","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1017\/S1092852900026304","article-title":"Treatment adherence and long-term outcomes","volume":"12","author":"Kane","year":"2007","journal-title":"CNS Spectr"},{"key":"B131","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/1471-244X-8-32","article-title":"Non-adherence to antipsychotic medication, relapse and rehospitalisation in recent-onset schizophrenia","volume":"8","author":"Morken","year":"2008","journal-title":"BMC Psychiatry."},{"key":"B132","first-page":"14","article-title":"Understanding and addressing adherence issues in schizophrenia: from theory to practice","volume":"68","author":"Weiden","year":"2007","journal-title":"J Clin Psychiatry"},{"key":"B133","doi-asserted-by":"publisher","first-page":"S63","DOI":"10.1192\/bjp.195.52.s63","article-title":"Clinical guideline recommendations for antipsychotic long-acting injections","volume":"52","author":"Kane","year":"2009","journal-title":"Br J Psychiatry Suppl"},{"key":"B134","doi-asserted-by":"publisher","first-page":"e46","DOI":"10.1192\/j.eurpsy.2020.45","article-title":"The association between insight and depressive symptoms in schizophrenia: undirected and Bayesian network analyses","volume":"63","author":"Amore","year":"2020","journal-title":"European Psychiatry."},{"key":"B135","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.schres.2011.07.019","article-title":"Are we addressing the 'right stuff' to enhance adherence in schizophrenia? Understanding the role of insight and attitudes towards medication","volume":"132","author":"Beck","year":"2011","journal-title":"Schizophr Res."},{"key":"B136","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/j.comppsych.2010.03.007","article-title":"Compliance and schizophrenia: the predictive potential of insight into illness, symptoms, and side effects","volume":"51","author":"Kao","year":"2010","journal-title":"Compr Psychiatry."},{"key":"B137","doi-asserted-by":"publisher","first-page":"449","DOI":"10.2147\/PPA.S124658","article-title":"Why do psychiatric patients stop antipsychotic medication? A systematic review of reasons for nonadherence to medication in patients with serious mental illness","volume":"11","author":"Velligan","year":"2017","journal-title":"Patient Prefer Adherence"},{"key":"B138","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1093\/schbul\/23.4.637","article-title":"Determinants of medication compliance in schizophrenia: empirical and clinical findings","volume":"23","author":"Fenton","year":"1997","journal-title":"Schizophr Bull."},{"key":"B139","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1093\/schbul\/sbn067","article-title":"Cross-sectional and longitudinal relationships between insight and attitudes toward medication and clinical outcomes in chronic schizophrenia","volume":"35","author":"Mohamed","year":"2009","journal-title":"Schizophr Bull."},{"key":"B140","doi-asserted-by":"publisher","first-page":"990","DOI":"10.4088\/JCP.08m04221","article-title":"Medication nonadherence and treatment outcome in patients with schizophrenia or schizoaffective disorder with suboptimal prior response","volume":"70","author":"Lindenmayer","year":"2009","journal-title":"J Clin Psychiatry."},{"key":"B141","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/S0924-9338(01)00581-8","article-title":"Predictors of compliance with neuroleptic medication among inpatients with schizophrenia: a discriminant function analysis","volume":"16","author":"Donohoe","year":"2001","journal-title":"Eur Psychiatry."},{"key":"B142","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/S0920-9964(01)00312-7","article-title":"Predictors of medication discontinuation by patients with first-episode schizophrenia and schizoaffective disorder","volume":"57","author":"Robinson","year":"2002","journal-title":"Schizophr Res."},{"key":"B143","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/S0920-9964(02)00314-6","article-title":"Cognitive predictors of medication adherence among middle-aged and older outpatients with schizophrenia","volume":"63","author":"Jeste","year":"2003","journal-title":"Schizophr Res."},{"key":"B144","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.4088\/JCP.v64n1105","article-title":"Partial compliance and patient consequences in schizophrenia: our patients can do better","volume":"64","author":"Keith","year":"2003","journal-title":"J Clin Psychiatry"},{"key":"B145","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1097\/00005053-199309000-00005","volume":"181","author":"Adams","year":"1993","journal-title":"J Nerv Ment Dis."},{"key":"B146","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1017\/S0033291700038228","article-title":"A two-year prospective study of treatment compliance in patients with schizophrenia","volume":"22","author":"Buchanan","year":"1992","journal-title":"Psychol Med."},{"key":"B147","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1192\/bjp.169.4.444","article-title":"Psychological predictors of insight and compliance in psychotic patients","volume":"169","author":"Kemp","year":"1996","journal-title":"Br J Psychiatry."},{"key":"B148","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.schres.2011.11.008","article-title":"Symptom severity and attitudes toward medication: impacts on adherence in outpatients with schizophrenia","volume":"134","author":"Yang","year":"2012","journal-title":"Schizophr Res."},{"key":"B149","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1111\/j.1600-0447.2012.01911.x","article-title":"Predictors of medication adherence in patients with schizophrenia and bipolar disorder","volume":"127","author":"J\u00f3nsd\u00f3ttir","year":"2013","journal-title":"Acta Psychiatr Scand."},{"key":"B150","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.psychres.2007.07.027","article-title":"Collaboration in outpatient antipsychotic drug treatment: analysis of potentially influencing factors","volume":"161","author":"Klingberg","year":"2008","journal-title":"Psychiatry Res."},{"key":"B151","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1111\/j.1751-7893.2010.00174.x","article-title":"Is there an association between neurocognitive performance and medication adherence in first episode psychosis?","volume":"4","author":"Lepage","year":"2010","journal-title":"Early Interv Psychiatry."},{"key":"B152","doi-asserted-by":"publisher","first-page":"106","DOI":"10.4088\/JCP.v69n0114","article-title":"Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomized, double-blind, flexible-dose, multicenter study","volume":"69","author":"Perkins","year":"2008","journal-title":"J Clin Psychiatry."},{"key":"B153","doi-asserted-by":"publisher","first-page":"211","DOI":"10.4088\/JCP.v65n0211","article-title":"A pilot study of barriers to medication adherence in schizophrenia","volume":"65","author":"Hudson","year":"2004","journal-title":"J Clin Psychiatry."},{"key":"B154","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1034\/j.1600-0447.2000.102003203.x","article-title":"Medication adherence in psychosis: predictors and impact on outcome. A 2-year follow-up of first-admitted subjects","volume":"102","author":"Verdoux","year":"2000","journal-title":"Acta Psychiatr Scand."},{"key":"B155","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1093\/oxfordjournals.schbul.a006853","article-title":"Negative symptoms of schizophrenia and compliance with medication","volume":"27","author":"Tattan","year":"2001","journal-title":"Schizophr Bull."},{"key":"B156","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.4088\/JCP.v65n0908","article-title":"Compliance in schizophrenia: psychopathology, side effects, and patients' attitudes toward the illness and medication","volume":"65","author":"Rettenbacher","year":"2004","journal-title":"J Clin Psychiatry."},{"key":"B157","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1093\/oxfordjournals.schbul.a006898","article-title":"A prospective study of factors influencing adherence to a continuous neuroleptic treatment program in schizophrenia patients during 2 years","volume":"27","author":"Linden","year":"2001","journal-title":"Schizophr Bull."},{"key":"B158","doi-asserted-by":"publisher","first-page":"20","DOI":"10.4088\/JCP.9096su1cc.04","article-title":"Strategies for improving treatment adherence in schizophrenia and schizoaffective disorder","volume":"71","author":"Goff","year":"2010","journal-title":"J Clin Psychiatry."},{"key":"B159","doi-asserted-by":"publisher","first-page":"318","DOI":"10.3109\/15622975.2012.696143","article-title":"World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance","volume":"13","author":"Hasan","year":"2012","journal-title":"World J Biol Psychiatry."},{"key":"B160","doi-asserted-by":"publisher","first-page":"S41","DOI":"10.1517\/14740338.2014.947260","article-title":"Adherence to therapy and adverse drug reactions: is there a link?","volume":"13","author":"Leporini","year":"2014","journal-title":"Expert Opin Drug Saf."},{"key":"B161","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.cger.2012.01.008","article-title":"Medication adherence to multidrug regimens","volume":"28","author":"Marcum","year":"2012","journal-title":"Clin Geriatr Med."},{"key":"B162","doi-asserted-by":"publisher","first-page":"129","DOI":"10.5455\/msm.2016.28.129-132","article-title":"Medication adherence in elderly with polypharmacy living at home. a systematic review of existing studies","volume":"28","author":"Zelko","year":"2016","journal-title":"Mater Sociomed."},{"key":"B163","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1176\/ps.2007.58.4.489","article-title":"Long-term antipsychotic polypharmacy in the VA health system: patient characteristics and treatment patterns","volume":"58","author":"Kreyenbuhl","year":"2007","journal-title":"Psychiatr Serv."},{"key":"B164","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1097\/YIC.0b013e3281084ea8","article-title":"Factors associated with antipsychotic dosing in psychiatric inpatients: a prospective study","volume":"22","author":"Barbui","year":"2007","journal-title":"Int Clin Psychopharmacol."},{"key":"B165","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1176\/appi.ajp.161.4.700","article-title":"Multiple versus single antipsychotic agents for hospitalized psychiatric patients: case-control study of risks versus benefits","volume":"161","author":"Centorrino","year":"2004","journal-title":"Am J Psychiatry."},{"key":"B166","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.schres.2006.02.023","article-title":"Long-term combination antipsychotic treatment in VA patients with schizophrenia","volume":"84","author":"Kreyenbuhl","year":"2006","journal-title":"Schizophr Res."},{"key":"B167","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1007\/s40265-021-01556-4","article-title":"Antipsychotic polypharmacy for the management of schizophrenia: evidence and recommendations","volume":"81","author":"L\u00e4hteenvuo","year":"2021","journal-title":"Drugs."},{"key":"B168","doi-asserted-by":"publisher","first-page":"354","DOI":"10.4088\/JCP.v65n0311","article-title":"Adherence to conventional and atypical antipsychotics after hospital discharge","volume":"65","author":"Diaz","year":"2004","journal-title":"J Clin Psychiatry."},{"key":"B169","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1097\/00131746-200511000-00003","article-title":"Strategies for improving adherence to second-generation antipsychotics in patients with schizophrenia by increasing ease of use","volume":"11","author":"Burton","year":"2005","journal-title":"J Psychiatr Pract."},{"key":"B170","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.schres.2006.11.015","article-title":"The use of electronic monitoring (MEMS) to evaluate antipsychotic compliance in outpatients with schizophrenia","volume":"90","author":"Remington","year":"2007","journal-title":"Schizophr Res."},{"key":"B171","doi-asserted-by":"crossref","DOI":"10.4102\/sajpsychiatry.v24i0.1124","article-title":"Antipsychotic medication non-adherence among schizophrenia patients in Central Ethiopia","volume-title":"South Afr J Psychiatry","author":"Tareke","year":"2018"},{"key":"B172","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1111\/j.1440-1819.2012.02376.x","article-title":"Effects of antipsychotic polypharmacy on side-effects and concurrent use of medications in schizophrenic outpatients","volume":"66","author":"Hashimoto","year":"2012","journal-title":"Psychiatry Clin Neurosci."},{"key":"B173","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1097\/YCO.0b013e3283642da4","article-title":"Medication nonadherence and psychiatry","volume":"26","author":"Chapman","year":"2013","journal-title":"Curr Opin Psychiatry."},{"key":"B174","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/1471-244X-14-111","article-title":"Efficacy of shared decision making on treatment satisfaction for patients with first-admission schizophrenia: study protocol for a randomised controlled trial","volume":"14","author":"Ishii","year":"2014","journal-title":"BMC Psychiatry."},{"key":"B175","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s12991-020-00293-4","article-title":"The role of shared decision-making in improving adherence to pharmacological treatments in patients with schizophrenia: a clinical review","volume":"19","author":"Fiorillo","year":"2020","journal-title":"Ann Gen Psychiatry"},{"key":"B176","doi-asserted-by":"publisher","first-page":"91","DOI":"10.2174\/157488411796151101","article-title":"From treatment adherence to advanced shared decision making: new professional strategies and attitudes in mental health care","volume":"6","author":"Tibaldi","year":"2011","journal-title":"Curr Clin Pharmacol."},{"key":"B177","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s12888-017-1218-1","article-title":"Feasibility and efficacy of shared decision making for first-admission schizophrenia: a randomized clinical trial","volume":"17","author":"Ishii","year":"2017","journal-title":"BMC Psychiatry."},{"key":"B178","doi-asserted-by":"publisher","first-page":"761","DOI":"10.3389\/fpsyt.2020.00761","article-title":"Treating schizophrenia: open conversations and stronger relationships through psychoeducation and shared decision-making","volume":"11","author":"Mucci","year":"2020","journal-title":"Front Psychiatry."},{"key":"B179","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.psychres.2014.11.002","article-title":"A systematic review of factors influencing adherence to antipsychotic medication in schizophrenia-spectrum disorders","volume":"225","author":"Sendt","year":"2015","journal-title":"Psychiatry Res."},{"key":"B180","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1111\/inm.12771_1","article-title":"Chinese mental health professionals' perceptions of shared decision-making regarding people diagnosed with schizophrenia: a qualitative study","volume":"30","author":"Huang","year":"2021","journal-title":"Int J Ment Health Nurs."},{"key":"B181","doi-asserted-by":"publisher","first-page":"260","DOI":"10.5498\/wjp.v10.i11.260","article-title":"Testing the hypothesis of subtypes of nonadherence in schizophrenia and schizoaffective disorder: a prospective study","volume":"10","author":"Vega","year":"2020","journal-title":"World J Psychiatry."},{"key":"B182","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.apnu.2018.08.003","article-title":"Therapeutic alliance, relationship building, and communication strategies-for the schizophrenia population: an integrative review","volume":"33","author":"Harris","year":"2019","journal-title":"Arch Psychiatr Nurs."},{"key":"B183","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/1744-859X-12-14","article-title":"Therapeutic alliance in early schizophrenia spectrum disorders: a cross-sectional study","volume":"12","author":"Johansen","year":"2013","journal-title":"Ann Gen Psychiatry"},{"key":"B184","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1055\/s-2003-39985","article-title":"Schizophrenic patients' subjective reasons for compliance and noncompliance with neuroleptic treatment","volume":"36","author":"L\u00f6ffler","year":"2003","journal-title":"Pharmacopsychiatry."},{"key":"B185","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1001\/archpsyc.62.7.717","article-title":"Attitudes toward antipsychotic medication: the impact of clinical variables and relationships with health professionals","volume":"62","author":"Day","year":"2005","journal-title":"Arch Gen Psychiatry."},{"key":"B186","volume-title":"Medicines Adherence: Involving Patients in Decisions About Prescribed Medicines and Supporting Adherence","year":"2009"},{"key":"B187","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.biopsych.2004.06.023","article-title":"Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria","volume":"56","author":"Green","year":"2004","journal-title":"Biol Psychiatry."},{"key":"B188","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1176\/appi.ajp.2007.07010042","article-title":"The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity","volume":"165","author":"Nuechterlein","year":"2008","journal-title":"Am J Psychiatry."},{"key":"B189","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1093\/schbul\/sbm145","article-title":"Social cognition in schizophrenia: an NIMH workshop on definitions, assessment, and research opportunities","volume":"34","author":"Green","year":"2008","journal-title":"Schizophr Bull."},{"key":"B190","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1002\/wps.20734","article-title":"Experimental approaches to social disconnection in the general community: can we learn from schizophrenia research?","volume":"19","author":"Green","year":"2020","journal-title":"World Psychiatry."},{"key":"B191","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1002\/wps.20914","article-title":"Metacognition in psychosis: a renewed path to understanding of core disturbances and recovery-oriented treatment","volume":"20","author":"Lysaker","year":"2021","journal-title":"World Psychiatry."},{"key":"B192","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1002\/wps.20774","article-title":"The evolution of Kraepelin's nosological principles","volume":"19","author":"Heckers","year":"2020","journal-title":"World Psychiatry."},{"key":"B193","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.schres.2022.01.029","article-title":"The Cognitive Assessment Interview (CAI): association with neuropsychological scores and real-life functioning in a large sample of Italian subjects with schizophrenia","volume":"241","author":"Giordano","year":"2022","journal-title":"Schizophr Res."},{"key":"B194","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1111\/acps.12374","article-title":"Second-generation antipsychotic effect on cognition in patients with schizophrenia\u2013a meta-analysis of randomized clinical trials","volume":"131","author":"Nielsen","year":"2015","journal-title":"Acta Psychiatr Scand."},{"key":"B195","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1007\/s00415-019-09493-9","article-title":"Physical exercise improves quality of life, depressive symptoms, and cognition across chronic brain disorders: a transdiagnostic systematic review and meta-analysis of randomized controlled trials","volume":"268","author":"Dauwan","year":"2021","journal-title":"J Neurol."},{"key":"B196","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.neubiorev.2021.01.005","article-title":"In- and outpatient lifestyle interventions on diet and exercise and their effect on physical and psychological health: a systematic review and meta-analysis of randomised controlled trials in patients with schizophrenia spectrum disorders and first episode of psychosis","volume":"125","author":"Fern\u00e1ndez-Abascal","year":"2021","journal-title":"Neurosci Biobehav Rev."},{"key":"B197","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1093\/schbul\/sbw115","article-title":"Aerobic exercise improves cognitive functioning in people with schizophrenia: a systematic review and meta-analysis","volume":"43","author":"Firth","year":"2017","journal-title":"Schizophr Bull."},{"key":"B198","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ctcp.2018.04.003","article-title":"Mindful exercise versus non-mindful exercise for schizophrenia: a systematic review and meta-analysis of randomized controlled trials","volume":"32","author":"Li","year":"2018","journal-title":"Complement Ther Clin Pract."},{"key":"B199","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1002\/cpp.2490","article-title":"Towards a neurocognitive approach to dance movement therapy for mental health: a systematic review","volume":"28","author":"Millman","year":"2021","journal-title":"Clin Psychol Psychother."},{"key":"B200","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.cpr.2017.05.002","article-title":"Effectiveness of psychoeducational interventions for family carers of people with psychosis: a systematic review and meta-analysis","volume":"56","author":"Sin","year":"2017","journal-title":"Clin Psychol Rev."},{"key":"B201","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.schres.2007.07.022","article-title":"Effectiveness of psychoeducation for relapse, symptoms, knowledge, adherence and functioning in psychotic disorders: a meta-analysis","volume":"96","author":"Lincoln","year":"2007","journal-title":"Schizophr Res."},{"key":"B202","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1002\/wps.20799","article-title":"Brain networks and cognitive impairment in psychiatric disorders","volume":"19","author":"Menon","year":"2020","journal-title":"World Psychiatry."},{"key":"B203","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1002\/wps.20759","article-title":"Neurocognitive deficits in schizophrenia are likely to be less severe and less related to the disorder than previously thought","volume":"19","author":"Moritz","year":"2020","journal-title":"World Psychiatry."},{"key":"B204","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1177\/0004867419853348","article-title":"A systematic review of factors that influence the efficacy of cognitive remediation therapy in schizophrenia","volume":"53","author":"Reser","year":"2019","journal-title":"Aust N Z J Psychiatry."},{"key":"B205","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/npp.2011.251","article-title":"Cognitive training for impaired neural systems in neuropsychiatric illness","volume":"37","author":"Vinogradov","year":"2012","journal-title":"Neuropsychopharmacology."},{"key":"B206","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1177\/0269881114560184","article-title":"Facial affect processing deficits in schizophrenia: a meta-analysis of antipsychotic treatment effects","volume":"29","author":"Gabay","year":"2015","journal-title":"J Psychopharmacol."},{"key":"B207","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1177\/0269881105057002","article-title":"The impact of atypical antipsychotic medications on long-term memory dysfunction in schizophrenia spectrum disorder: a quantitative review","volume":"20","author":"Thornton","year":"2006","journal-title":"J Psychopharmacol."},{"key":"B208","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1017\/S146114570500516X","article-title":"A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia","volume":"8","author":"Woodward","year":"2005","journal-title":"Int J Neuropsychopharmacol."},{"key":"B209","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1017\/S1461145712001277","article-title":"Efficacy and safety of individual second-generation vs. first-generation antipsychotics in first-episode psychosis: a systematic review and meta-analysis","volume":"16","author":"Zhang","year":"2013","journal-title":"Int J Neuropsychopharmacol."},{"key":"B210","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.neubiorev.2021.03.028","article-title":"The effect of antipsychotics on the cognitive performance of individuals with psychotic disorders: network meta-analyses of randomized controlled trials","volume":"126","author":"Baldez","year":"2021","journal-title":"Neurosci Biobehav Rev."},{"key":"B211","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1001\/archpsyc.64.6.633","article-title":"Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial","volume":"64","author":"Keefe","year":"2007","journal-title":"Arch Gen Psychiatry."},{"key":"B212","first-page":"62","article-title":"Psychopharmacological treatment of cognitive deficits in Schizophrenia and mood disorders","volume":"24","author":"Vita","year":"2018","journal-title":"Off J Ital Soc Psychopathol."},{"key":"B213","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1017\/S1355617714000162","article-title":"Predictors for improvement of problem-solving during cognitive remediation for patients with Schizophrenia","volume":"20","author":"Rodewald","year":"2014","journal-title":"J Int Neuropsychol Soc."},{"key":"B214","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.schres.2013.08.011","article-title":"Predictors of cognitive and functional improvement and normalization after cognitive remediation in patients with schizophrenia","volume":"150","author":"Vita","year":"2013","journal-title":"Schizophr Res."},{"key":"B215","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1111\/j.1440-1819.2012.02390.x","article-title":"Clinical correlates associated with cognitive dysfunction in people with schizophrenia","volume":"66","author":"Tanaka","year":"2012","journal-title":"Psychiatry Clin Neurosci."},{"key":"B216","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s00406-014-0511-y","article-title":"Antipsychotic-induced parkinsonism is associated with working memory deficits in schizophrenia-spectrum disorders","volume":"265","author":"Potvin","year":"2015","journal-title":"Eur Arch Psychiatry Clin Neurosci."},{"key":"B217","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/S0006-3223(98)00167-X","article-title":"Extrapyramidal symptoms and neuropsychological deficits in schizophrenia","volume":"45","author":"Palmer","year":"1999","journal-title":"Biol Psychiatry."},{"key":"B218","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0306-4530(02)00115-4","article-title":"Cognitive effects and antipsychotic treatment","volume":"28","author":"Kasper","year":"2003","journal-title":"Psychoneuroendocrinology."},{"key":"B219","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1093\/schbul\/sbt125","article-title":"Spontaneous Parkinsonism is associated with cognitive impairment in antipsychotic-naive patients with first-episode psychosis: a 6-month follow-up study","volume":"40","author":"Cuesta","year":"2013","journal-title":"Schizophr Bull."},{"key":"B220","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1176\/appi.ajp.158.8.1276","article-title":"Spatial working memory deficits in schizophrenia: relationship with tardive dyskinesia and negative symptoms","volume":"158","author":"Pantelis","year":"2001","journal-title":"Am J Psychiatry."},{"key":"B221","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.pnpbp.2013.06.013","article-title":"Tardive dyskinesia is associated with greater cognitive impairment in schizophrenia","volume":"46","author":"Wu","year":"2013","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry."},{"key":"B222","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.schres.2005.07.034","article-title":"Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trial","volume":"80","author":"Miller","year":"2005","journal-title":"Schizophr Res."},{"key":"B223","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1006\/brcg.1993.1044","article-title":"Cognitive dysfunction in schizophrenia: organic vulnerability factor or state marker for tardive dyskinesia?","volume":"23","author":"Waddington","year":"1993","journal-title":"Brain Cogn."},{"key":"B224","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1002\/j.2051-5545.2009.tb00199.x","article-title":"Metabolic syndrome in people with schizophrenia: a review","volume":"8","author":"De Hert","year":"2009","journal-title":"World Psychiatry."},{"key":"B225","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.schres.2005.07.015","article-title":"The clinical antipsychotic trials of intervention effectiveness (CATIE) schizophrenia trial: clinical comparison of subgroups with and without the metabolic syndrome","volume":"80","author":"Meyer","year":"2005","journal-title":"Schizophr Res."},{"key":"B226","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1097\/PRA.0000000000000065","article-title":"Associations between components of metabolic syndrome and cognition in patients with schizophrenia","volume":"21","author":"Goughari","year":"2015","journal-title":"J Psychiatr Pract."},{"key":"B227","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.schres.2012.08.034","article-title":"Diabetes is associated with lower global cognitive function in schizophrenia","volume":"142","author":"Takayanagi","year":"2012","journal-title":"Schizophr Res."},{"key":"B228","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1002\/phar.2652","article-title":"Anticholinergic medication burden and cognitive function in participants of the ASPREE study","volume":"42","author":"Broder","year":"2022","journal-title":"Pharmacotherapy."},{"key":"B229","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.sapharm.2019.05.020","article-title":"Anticholinergic burden and risk of cognitive impairment in elderly nursing home residents with depression","volume":"16","author":"Chatterjee","year":"2020","journal-title":"Res Social Adm Pharm."},{"key":"B230","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1080\/14740338.2020.1811227","article-title":"Anticholinergic medications and risk of dementia in older adults: where are we now?","volume":"19","author":"Chatterjee","year":"2020","journal-title":"Expert Opin Drug Saf."},{"key":"B231","doi-asserted-by":"publisher","first-page":"225","DOI":"10.2147\/CIA.S5358","article-title":"The cognitive impact of anticholinergics: a clinical review","volume":"4","author":"Campbell","year":"2009","journal-title":"Clin Interv Aging."},{"key":"B232","doi-asserted-by":"publisher","first-page":"e1284","DOI":"10.4088\/JCP.17m11523","article-title":"Anticholinergic burden and cognition in older patients with schizophrenia","volume":"78","author":"Tsoutsoulas","year":"2017","journal-title":"J Clin Psychiatry."},{"key":"B233","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1038\/s41386-021-01057-8","article-title":"Genome-wide association study accounting for anticholinergic burden to examine cognitive dysfunction in psychotic disorders","volume":"46","author":"Eum","year":"2021","journal-title":"Neuropsychopharmacology."},{"key":"B234","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/j.schres.2019.01.016","article-title":"Verbal learning deficits associated with increased anticholinergic burden are attenuated with targeted cognitive training in treatment refractory schizophrenia patients","volume":"208","author":"Joshi","year":"2019","journal-title":"Schizophr Res."},{"key":"B235","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1176\/appi.ajp.2009.09010017","article-title":"The cognitive cost of anticholinergic burden: decreased response to cognitive training in schizophrenia","volume":"166","author":"Vinogradov","year":"2009","journal-title":"Am J Psychiatry."},{"key":"B236","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1176\/appi.ajp.161.1.116","article-title":"Association of anticholinergic load with impairment of complex attention and memory in schizophrenia","volume":"161","author":"Minzenberg","year":"2004","journal-title":"Am J Psychiatry."},{"key":"B237","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1017\/S1041610219000358","article-title":"Benzodiazepine use among older adults with schizophrenia spectrum disorder: prevalence and associated factors in a multicenter study","volume":"32","author":"Schuster","year":"2020","journal-title":"Int Psychogeriatr."},{"key":"B238","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.euroneuro.2020.03.010","article-title":"Persistent negative symptoms in recent-onset psychosis: relationship to treatment response and psychosocial functioning","volume":"34","author":"Bucci","year":"2020","journal-title":"Eur Neuropsychopharmacol."},{"key":"B239","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1002\/wps.20385","article-title":"The current conceptualization of negative symptoms in schizophrenia","volume":"16","author":"Marder","year":"2017","journal-title":"World Psychiatry."},{"key":"B240","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1002\/wps.20706","article-title":"The revised German evidence- and consensus-based schizophrenia guideline","volume":"19","author":"Gaebel","year":"2020","journal-title":"World Psychiatry."},{"key":"B241","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1002\/wps.20800","article-title":"RDoC at 10: changing the discourse for psychopathology","volume":"19","author":"Sanislow","year":"2020","journal-title":"World Psychiatry."},{"key":"B242","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1002\/wps.20730","article-title":"Validity and utility of hierarchical taxonomy of psychopathology (HiTOP): I. Psychosis superspectrum","volume":"19","author":"Kotov","year":"2020","journal-title":"World Psychiatry."},{"key":"B243","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1002\/wps.20825","article-title":"An organization- and category-level comparison of diagnostic requirements for mental disorders in ICD-11 and DSM-5","volume":"20","author":"First","year":"2021","journal-title":"World Psychiatry."},{"key":"B244","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1002\/wps.20824","article-title":"Hierarchical models of psychopathology: empirical support, implications, and remaining issues","volume":"20","author":"Lahey","year":"2021","journal-title":"World Psychiatry."},{"key":"B245","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1002\/wps.20844","article-title":"Validity and utility of hierarchical taxonomy of psychopathology (HiTOP): II. Externalizing superspectrum","volume":"20","author":"Krueger","year":"2021","journal-title":"World Psychiatry."},{"key":"B246","doi-asserted-by":"publisher","first-page":"789179","DOI":"10.3389\/fpsyt.2021.789179","article-title":"Gender differences in clinical and psychosocial features among persons with schizophrenia: a mini review","volume":"12","author":"Giordano","year":"2021","journal-title":"Front Psychiatry."},{"key":"B247","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.euroneuro.2018.03.013","article-title":"Functional connectivity of the ventral tegmental area and avolition in subjects with schizophrenia: a resting state functional MRI study","volume":"28","author":"Giordano","year":"2018","journal-title":"Eur Neuropsychopharmacol."},{"key":"B248","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1177\/0269881114562092","article-title":"Dissecting negative symptoms in schizophrenia: opportunities for translation into new treatments","volume":"29","author":"Foussias","year":"2015","journal-title":"J Psychopharmacol."},{"key":"B249","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.schres.2016.04.046","article-title":"Dissecting negative symptoms of schizophrenia: history, assessment, pathophysiological mechanisms and treatment","volume":"186","author":"Galderisi","year":"2017","journal-title":"Schizophr Res."},{"key":"B250","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1093\/schbul\/sbj054","article-title":"Subdomains within the negative symptoms of schizophrenia: commentary","volume":"32","author":"Kirkpatrick","year":"2006","journal-title":"Schizophr Bull."},{"key":"B251","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.schres.2011.07.003","article-title":"Apathy, cognitive deficits and functional impairment in schizophrenia","volume":"133","author":"Konstantakopoulos","year":"2011","journal-title":"Schizophr Res."},{"key":"B252","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1093\/schbul\/sbu170","article-title":"Treatments of negative symptoms in schizophrenia: meta-analysis of 168 randomized placebo-controlled trials","volume":"41","author":"Fusar-Poli","year":"2015","journal-title":"Schizophr Bull."},{"key":"B253","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.eurpsy.2019.01.015","article-title":"The efficacy of cariprazine in negative symptoms of schizophrenia: post hoc analyses of PANSS individual items and PANSS-derived factors","volume":"58","author":"Fleischhacker","year":"2019","journal-title":"Eur Psychiatry."},{"key":"B254","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1007\/s00406-018-0869-3","article-title":"Antipsychotic drugs for patients with schizophrenia and predominant or prominent negative symptoms: a systematic review and meta-analysis","volume":"268","author":"Krause","year":"2018","journal-title":"Eur Arch Psychiatry Clin Neurosci."},{"key":"B255","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1016\/S0140-6736(17)30060-0","article-title":"Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial","volume":"389","author":"N\u00e9meth","year":"2017","journal-title":"Lancet."},{"key":"B256","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.schres.2016.05.014","article-title":"Primary and persistent negative symptoms: concepts, assessments and neurobiological bases","volume":"186","author":"Mucci","year":"2017","journal-title":"Schizophr Res."},{"key":"B257","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1093\/schbul\/sbx064","article-title":"Primary, enduring negative symptoms: an update on research","volume":"43","author":"Kirkpatrick","year":"2017","journal-title":"Schizophr Bull."},{"key":"B258","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/S0140-6736(19)31135-3","article-title":"Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis","volume":"394","author":"Huhn","year":"2019","journal-title":"Lancet."},{"key":"B259","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.euroneuro.2018.11.1105","article-title":"Efficacy, acceptability and tolerability of antipsychotics in patients with schizophrenia and comorbid substance use. A systematic review and meta-analysis","volume":"29","author":"Krause","year":"2019","journal-title":"Eur Neuropsychopharmacol."},{"key":"B260","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1002\/wps.20387","article-title":"Antipsychotic augmentation vs. monotherapy in schizophrenia: systematic review, meta-analysis and meta-regression analysis","volume":"16","author":"Galling","year":"2017","journal-title":"World Psychiatry."},{"key":"B261","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1093\/schbul\/11.3.440","volume":"11","author":"Carpenter","year":"1985","journal-title":"Schizophr Bull."},{"key":"B262","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/S0920-9964(00)00135-3","article-title":"Depression in schizophrenia: recognition and management in the USA","volume":"47","author":"Siris","year":"2001","journal-title":"Schizophr Res."},{"key":"B263","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1192\/bjp.154.2.207","article-title":"Negative and depressive symptoms in schizophrenia","volume":"154","author":"Kulhara","year":"1989","journal-title":"Br J Psychiatry."},{"key":"B264","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1176\/appi.ajp.157.9.1379","article-title":"Depression in schizophrenia: perspective in the era of \u201catypical\u201d antipsychotic agents","volume":"157","author":"Siris","year":"2000","journal-title":"Am J Psychiatry."},{"key":"B265","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1038\/sj.mp.4002136","article-title":"How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials","volume":"14","author":"Leucht","year":"2009","journal-title":"Mol Psychiatry."},{"key":"B266","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1111\/acps.12854","article-title":"Efficacy and safety of antidepressant augmentation of continued antipsychotic treatment in patients with schizophrenia","volume":"137","author":"Galling","year":"2018","journal-title":"Acta Psychiatr Scand."},{"key":"B267","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1176\/appi.ajp.2016.15081035","article-title":"Efficacy and safety of antidepressants added to antipsychotics for schizophrenia: a systematic review and meta-analysis","volume":"173","author":"Helfer","year":"2016","journal-title":"Am J Psychiatry."},{"key":"B268","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.schres.2016.05.003","article-title":"Secondary negative symptoms - a review of mechanisms, assessment and treatment","volume":"186","author":"Kirschner","year":"2017","journal-title":"Schizophr Res."},{"key":"B269","doi-asserted-by":"publisher","first-page":"e09","DOI":"10.4088\/JCP.13049tx3c","article-title":"Recognizing primary vs secondary negative symptoms and apathy vs expression domains","volume":"75","author":"Kirkpatrick","year":"2014","journal-title":"J Clin Psychiatry."},{"key":"B270","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.eurpsy.2007.03.010","article-title":"Clinical evaluation of negative symptoms in schizophrenia","volume":"22","author":"M\u00f6ller","year":"2007","journal-title":"Eur Psychiatry."},{"key":"B271","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/wps.20807","article-title":"Primary psychosis: more to know, much more to do","volume":"20","author":"Carpenter","year":"2021","journal-title":"World Psychiatry."},{"key":"B272","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.schres.2021.12.007","article-title":"We are not ready to abandon the current schizophrenia construct, but should be prepared to do so","volume":"242","author":"Galderisi","year":"2022","journal-title":"Schizophr Res."},{"key":"B273","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1002\/wps.20882","article-title":"The promise of machine learning in predicting treatment outcomes in psychiatry","volume":"20","author":"Chekroud","year":"2021","journal-title":"World Psychiatry."},{"key":"B274","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1055\/a-1211-2826","article-title":"Die \u201cPr\u00e4zisionspsychiatrie\u201d muss Teil der \u201cpersonalisierten Psychiatrie\u201d werden","volume":"88","author":"Giordano","year":"2020","journal-title":"Fortschr Neurol Psychiatr."}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2022.970210\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T12:31:30Z","timestamp":1662035490000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2022.970210\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,30]]},"references-count":274,"alternative-id":["10.3389\/fpsyt.2022.970210"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2022.970210","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,30]]},"article-number":"970210"}}